Guardant360® CDx by Guardant Health

Guardant Health, Inc.

Guardant360® CDx by Guardant Health

The first FDA-approved blood test for complete genomic testing

FDA Breakthrough Device Designation

Do you know anyone using Guardant360® CDx by Guardant Health?

The Guardant360 CDx test is a genomic testing option for solid cancers that has been approved by the FDA. It provides doctors with comprehensive results within a week of a simple blood draw, which allows for more efficient treatment decisions. Unlike traditional tissue biopsy methods, this blood test allows for a greater number of patients to benefit from targeted therapies that have been approved by the FDA. This test covers all genes recommended by the National Comprehensive Cancer Network, including the 55 most relevant to clinical care. Additionally, it has been approved as a companion diagnostic to identify patients with non-small cell lung cancer who may benefit from treatment with certain drugs such as TAGRISSO, RYBREVANT, ENHERTU and LUMAKRAS.

Guardant360® CDx by Guardant Health

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.

© 2023 Netspective Media LLC. All Rights Reserved.

Built on Feb 3, 2023 at 6:31am